POLI HARLOWE, MARIA CECILIA BERTA
Preferred name
POLI HARLOWE, MARIA CECILIA BERTA
Main Affiliation
Email
mpoli@alemana.cl
ORCID
0000-0001-6817-0573
Scopus Author ID
57214078113
64 results
Now showing 1 - 10 of 64
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, FATAL NEUROLOGICAL COMPLICATION POST HSCT IN A PEDIATRIC PATIENT WITH IMMUNODEFICIENCY DUE TO NFKB2 MUTATION(2024); ;Catalan, Paula ;Sotomayor, CristianWietstruck, Maria Angelica18 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN2COVID Phase I Randomized Trial(2023) ;Diego Garcia-Huidobro ;Carolina Iturriaga ;Guillermo Perez-Mateluna ;Paula FajuriNicolás SeverinoScopus© Citations 2 1 - Some of the metrics are blocked by yourconsent settings
Item type:Product, 15 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Treated with Tocilizumab(2020) ;Carmen Niño-Taravilla ;YazmĂn P. Espinosa-Vielma; ; Lorena I. Tapia<jats:p>We describe a case of Pediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in an 8-year-old child. The patient developed multiorgan dysfunction, including mixed shock, cardiac dysfunction with myocarditis, pneumonia, acute kidney failure, and gastrointestinal involvement characterized by inflammation of the wall of the bowel and pancreatitis. After treatment with Tocilizumab and corticoid therapy, he presented clinical improvement and normalization of inflammatory markers. PIMS-TS is a new disease developed in a small percentage of patients, so a high degree of suspicion is necessary to establish the diagnosis. Supportive care is of paramount importance. The use of Tocilizumab to control the inflammatory response is likely to be beneficial, but the best immunotherapeutic agent has not yet been established. Randomized clinical studies should be run to determine the best treatment.</jats:p>14Scopus© Citations 20 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Partial loss of function mutations in GINS4 lead to natural killer cell deficiency with neutropenia(2022) ;Matilde Conte ;Angelo Taglialatela ;Giuseppe Leuzzi ;Ivan ChinnSandra Salinas3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis(2018) ;Ivan K. Chinn ;Olive S. Eckstein ;Erin C. Peckham-Gregory ;Baruch R. GoldbergLisa R. Forbes<jats:title>Key Points</jats:title> <jats:p>Whole-exome sequencing may identify specific therapeutic opportunities for patients with HLH. HLH should be conceptualized as a critical illness phenotype driven by toxic activation of immune cells from different underlying mechanisms.</jats:p>Scopus© Citations 167 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, An integrated platform for concurrent structural and single-nucleotide variants improves copy-number detection and reveals pathogenic alleles in undiagnosed Mendelian families(Springer Science and Business Media LLC, 2025-12-31) ;Haowei Du ;Ming Yin Lun ;Lidiia Gagarina ;Jesse D. BengtssonChristopher M. Grochowski1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Abstract 5293: A molecular classification of gastric cancer in Chilean patients(2020) ;Mauricio P. Pinto ;Matias Muñoz-Medel ;Miguel Cordova-Delgado ;Ignacio N. RetamalGareth Owen<jats:title>Abstract</jats:title> <jats:p>Objective: Incidence and mortality rates of gastric cancer (GC) are characterized by their geographical heterogeneity. In Chile, GC is the leading cause of cancer death. To date, GC patients' response to standard therapies remains limited. A molecular classification of GCs may deliver better stratifications. Herein, we obtained clinical data, protein expression and genetic profiles in a cohort of Chilean patients and present a molecular classification that correlated with overall survival (OS) rates.</jats:p> <jats:p>Methods: A total of 71 patients were included. Clinical data were obtained from medical records; protein expression was analyzed by a Tissue MicroArray. We also performed Next Generation Sequencing to assess p53 status (WT or Mut). Supervised clustering was used to generate a molecular classification. Kaplan-Meier method was used to calculate OS. Hazard ratio was calculated by Cox regression.</jats:p> <jats:p>Results: We defined 5 GC subgroups: Epstein-Barr virus+ (EBV, n=9; 13%), Microsatellite Instable (MSI, n=9; 13%), E-cadherin loss (EMT-like, n=12; 17%). The remaining patients (those MSS-/EBV-/not EMT-like) were classified either as p53 WT (n=21; 30%) or p53 Mutated (n=20; 28%). According to subgroups, 5-year survival rates were: MSI=77,8%; EBV=43.2%; p53WT=43.5%; p53Mut=25% and EMT-like=16.7%. Hazard ratios for p53Mut and EMT-like were 5.1 (IC 95%: 1.16-22.41; p=0.031) and 6.81 (IC 95%: 1.48-31.24; p=0.014), respectively against the MSI group used as reference. This association is maintained in a multivariate model using age, gender and stage.</jats:p> <jats:p>Conclusions: Our study defined 5 GC subgroups. These are associated to OS rates. EMT-like and p53Mut subgroups displayed poorer survival. Future studies should explore actionable targets in these subsets in order to improve their survival.</jats:p> <jats:p>Citation Format: Mauricio P. Pinto, Matias Muñoz-Medel, Miguel Cordova-Delgado, Ignacio N. Retamal, Gareth Owen, Maria Loreto Bravo, Ricardo Armisen, Marcelo Garrido. A molecular classification of gastric cancer in Chilean patients [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5293.</jats:p>3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genomic Characterization of a Pediatric Cohort with Lymphoproliferative Disorders(2020); ;Forbes, Lisa ;Eckstein, Olive ;Gulati, NityaPeckham-Gregory, Erin1 - Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - TGFβ links EBV to multisystem inflammatory syndrome in children(Molecular Signatures Database (MSigDB), 2025);